Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enanta Pharmaceutica
(NQ:
ENTA
)
12.20
-0.06 (-0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Enanta Pharmaceutica
< Previous
1
2
3
4
Next >
Enanta Pharmaceuticals to Participate in Two Investor Conferences in June
June 02, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
May 18, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
May 09, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022
May 02, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
March 29, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
February 17, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
February 16, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 10, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
February 08, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021
February 01, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
November 22, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in December Investor Conferences
November 19, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program
November 18, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
November 15, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor
November 12, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
October 19, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
October 06, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
October 05, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs
October 04, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021
October 01, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Investor Conferences in September
September 07, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
August 23, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer
August 16, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
August 05, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
August 05, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021
July 29, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
July 14, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™
June 23, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.